Novartis steps up launch of Symjepi to fill in Mylan EpiPen gap, while Amneal has trouble with supply
Genmab looking for a $500M IPO and record-setting market cap
Charles River Labs plots 2020 opening for San Fran lab
Jazz Pharma acquiring pre-clinical pan-RAF inhibitor
*scroll through previous pages at the bottom to get older news*
Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe
